Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

Efficacy of highly active antiretroviral therapy in HIV-1 infected children.

van Rossum AM, Fraaij PL, de Groot R.

Lancet Infect Dis. 2002 Feb;2(2):93-102. Review.

PMID:
11901656
2.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
3.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
4.

Antiretroviral chemotherapy.

Saag MS, Schooley RT.

Curr Clin Top Infect Dis. 1998;18:154-79. Review. No abstract available.

PMID:
9779354
5.

Saquinavir soft-gel capsule: an updated review of its use in the management of HIV infection.

Figgitt DP, Plosker GL.

Drugs. 2000 Aug;60(2):481-516. Review.

PMID:
10983742
6.

Nelfinavir. A review of its therapeutic efficacy in HIV infection.

Jarvis B, Faulds D.

Drugs. 1998 Jul;56(1):147-67. Review.

PMID:
9664204
7.

Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience.

van Heeswijk RP, Veldkamp A, Mulder JW, Meenhorst PL, Lange JM, Beijnen JH, Hoetelmans RM.

Antivir Ther. 2001 Dec;6(4):201-29. Review.

PMID:
11878403
8.

Perspectives on HAART: switch maintenance therapy.

Leen CL.

Int J STD AIDS. 2003 Sep;14(9):577-82. Review.

PMID:
14511491
10.

Abacavir: a review of its clinical potential in patients with HIV infection.

Hervey PS, Perry CM.

Drugs. 2000 Aug;60(2):447-79. Review.

PMID:
10983741
11.

Efavirenz: a decade of clinical experience in the treatment of HIV.

Maggiolo F.

J Antimicrob Chemother. 2009 Nov;64(5):910-28. doi: 10.1093/jac/dkp334. Epub 2009 Sep 18. Review.

12.

Antiretroviral therapy response among HIV-2 infected patients: a systematic review.

Ekouevi DK, Tchounga BK, Coffie PA, Tegbe J, Anderson AM, Gottlieb GS, Vitoria M, Dabis F, Eholie SP.

BMC Infect Dis. 2014 Aug 26;14:461. doi: 10.1186/1471-2334-14-461. Review.

13.

Anti-HIV drugs for cancer therapeutics: back to the future?

Chow WA, Jiang C, Guan M.

Lancet Oncol. 2009 Jan;10(1):61-71. doi: 10.1016/S1470-2045(08)70334-6. Review.

PMID:
19111246
14.

Causes and consequences of incomplete HIV RNA suppression in clinical trials.

Pozniak A, Gupta RK, Pillay D, Arribas J, Hill A.

HIV Clin Trials. 2009 Sep-Oct;10(5):289-98. doi: 10.1310/hct1005-289. Review.

PMID:
19906623
15.

Immune reconstitution and vaccination outcome in HIV-1 infected children: present knowledge and future directions.

Cagigi A, Cotugno N, Giaquinto C, Nicolosi L, Bernardi S, Rossi P, Douagi I, Palma P.

Hum Vaccin Immunother. 2012 Dec 1;8(12):1784-94. doi: 10.4161/hv.21827. Epub 2012 Aug 21. Review.

16.

Long-term effect of highly active antiretroviral therapy on immunologic features in children.

Montagnani C, Chiappini E, Bonsignori F, Galli L, de Martino M.

Pediatr Infect Dis J. 2015 May;34(5 Suppl 1):S3-6. doi: 10.1097/INF.0000000000000659. Review.

PMID:
25894974
17.

Antiretroviral drugs in HIV-infected children.

ViganĂ² A, Manfredini V, Penagini F, Giacomet V, Zuccotti GV.

Pharmacol Res. 2011 Jul;64(1):1-3. doi: 10.1016/j.phrs.2011.01.007. Epub 2011 Jan 19. Review.

PMID:
21255650
18.

Tolerabilities of antiretrovirals in paediatric HIV infection.

Lemberg DA, Palasanthiran P, Goode M, Ziegler JB.

Drug Saf. 2002;25(14):973-91. Review.

PMID:
12408730
19.

[Pediatric HIV infections in developed countries: current situation and future challenges].

Frange P, Blanche S, Chaix ML.

Med Sci (Paris). 2014 May;30(5):551-7. doi: 10.1051/medsci/20143005019. Epub 2014 Jun 13. Review. French.

20.

The roles of genetic polymorphisms and human immunodeficiency virus infection in lipid metabolism.

de Almeida ER, Reiche EM, Kallaur AP, Flauzino T, Watanabe MA.

Biomed Res Int. 2013;2013:836790. doi: 10.1155/2013/836790. Epub 2013 Nov 12. Review.

Supplemental Content

Support Center